Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycystic Ovary Syndrome 2Neoplasms 2Diabetes Mellitus, Type 2 2Thyroid Cancer, Papillary 1Solid Cancers 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liposarcoma 1Leukoplakia, Oral 1Carcinoma, Renal Cell 1Breast Neoplasms 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

Dexamethasone 2ixazomib 1birtamimab 1Standard of Care 1Rosiglitazone 1Neurofeedback 1Methotrexate 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hormones 1Exercise 1Cyclophosphamide 1Control Groups 1Cholinesterase Inhibitors 1Calcium Dobesilate 1Bortezomib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Alzheimer Disease × Rosiglitazone × Clear all
NCT00428090 2017-05-19

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

GlaxoSmithKline

Phase 3 Completed
862 enrolled 36 charts
Lymphoid

Alzheimer Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡